Avenue Therapeutics
menu
  • About
    • Management Team
    • Board of Directors
  • Pipeline
    • BAER-101
    • IV Tramadol
    • AJ201
  • Publications
  • Investors
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
      • Analyst Coverage
    • Stock Data
      • Quote
      • Charts
      • Historical Data
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Events
  • Contact Us
    • Careers
      • Email Alerts

Press Releases

Investors

Investors

  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Analyst Coverage
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Nov 14, 2024

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Oct 09, 2024

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

Sep 03, 2024

Avenue Therapeutics to Participate in Upcoming Investor Conferences

Aug 09, 2024

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Jun 20, 2024

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

May 16, 2024

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

May 15, 2024

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Apr 29, 2024

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

Apr 24, 2024

Avenue Therapeutics Announces Reverse Stock Split

Mar 25, 2024

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Privacy
  • Disclaimer
  • Contact Us


twitter icon linked-in icon
Website Design, Maintenance and Hosting by Tidal Media Group
Copyright ©2025 Avenue Therapeutics.

logo